Dear Ms. Gao:

Please refer to your Supplemental New Drug Application (sNDA) dated August 11, 2015, received August 11, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Afinitor® (everolimus) tablets for oral administration, 2.5 mg, 5 mg, 7.5 mg, and 10 mg.

We acknowledge receipt of your amendment dated December 9, 2015.

This Prior Approval supplemental new drug application provides for updating section 5 “EMBRYO-FETAL TOXICITY”, section 8 “USE IN SPECIFIC POPULATIONS”, and section 17 “PATIENT COUNSELING INFORMATION” of the Package Insert (PI), and to update the Patient Package Insert (PPI) to meet the requirements of the “Pregnancy and Lactation Labeling Rule (PLLR)”.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling text for the package insert and text for the patient package insert, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sakar Wahby, Regulatory Project Manager, at (240) 402-5364 or email me at sakar.wahby@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Amna Ibrahim, MD
Deputy Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

**ENCLOSURE(S):**
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

AMNA IBRAHIM
02/04/2016